---
title: "Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285146405.md"
description: "Ultragenyx Pharmaceutical's CFO, Howard Horn, sold 4,683 shares valued at $116,606 on May 4, 2026, attracting investor attention. Spark's AI Analyst rates RARE stock as Neutral due to weak financial performance, ongoing losses, and a reduced equity base. Despite potential upside from upcoming corporate events and revenue growth guidance, technicals remain weak, and valuation signals are constrained by negative earnings. Year-to-date, the stock has seen a 7.70% price performance with a market cap of $2.44 billion."
datetime: "2026-05-05T02:07:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285146405.md)
  - [en](https://longbridge.com/en/news/285146405.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285146405.md)
---

# Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing

New insider activity at Ultragenyx Pharmaceutical ( (RARE) ) has taken place on May 4, 2026.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ultragenyx Pharmaceutical’s Chief Financial Officer, Howard Horn, has recently sold 4,683 shares of the company’s stock in a transaction valued at $116,606. This insider move draws attention to trading activity within the company’s executive ranks and may be closely watched by investors tracking leadership’s confidence and portfolio decisions.

**Spark’s Take on RARE Stock**

According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.

The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a sharply reduced equity base. Earnings call and corporate-event catalysts (2026 revenue growth guidance, expense-reduction plan toward 2027 profitability, and multiple FDA review milestones) provide meaningful upside potential, but technicals remain weak and valuation signals are constrained by negative earnings.

To see Spark’s full report on RARE stock, click here.

**More about Ultragenyx Pharmaceutical**

**YTD Price Performance:** 7.70%

**Average Trading Volume:** 2,027,496

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $2.44B

### Related Stocks

- [RARE.US](https://longbridge.com/en/quote/RARE.US.md)

## Related News & Research

- [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)
- [Jim Cramer Says Nvidia Should Stay Inside China’s AI Boom, Not Walk Away](https://longbridge.com/en/news/286804523.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [How network intelligence can help businesses anticipate risks, ensure uptime, and deliver on AI](https://longbridge.com/en/news/286815400.md)
- [Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances](https://longbridge.com/en/news/286947828.md)